AIM: To investigate the prognostic role of genomic stability and copy number alterations (CNAs) pancreatic neuroendocrine tumors (PanNETs). METHODS: A high-resolution array-based comparative genomic hybridization approach was utilized in order to investigate and quantify chromosomal aberrations in a panel of 37 primary PanNET and 11 metastatic samples. DNA samples were extracted from formalin-fixed and paraffin-embedded tumor specimen. Genomic findings were correlated with histopathological and immunohistochemical data. Moreover, the dataset was subjected to employing an unsupervised hierarchical clustering analysis approach utilizing Euclidean distance and average linkage and associations between genomically defined tumor groups and recurrent CNAs or clinicopathological features of the study group were assessed. RESULTS: Numerous chromosomal aberrations were recurrently detected in both, primary tumor samples and metastases. Copy number gains were most frequently observed at 06p22.2-p22.1 (27.1%), 17p13.1 (20.8%), 07p21.3-p21.2 (18.8%), 09q34.11 (18.8%). Genomic losses were significantly less frequent and the only recurrent aberration affected 08q24.3 (6.3%). Moreover, we detected a high degree of genomic heterogeneity between primary tumors and metastatic lesions. Unsupervised hierarchical clustering of loci affected by CNAs in more than 3 primary tumor samples revealed two genetically distinct tumor groups as well as two chromosomal clusters of genomic imbalances indicating a small subset of tumors with common molecular features (13.5%). Aberrations affecting 6p22.2-22.1, 8q24.3, 9q34.11 and 17p13.1 (P = 0.011; 0.003; 0.003; 0.001), were significantly associated with a poorer survival prognosis. CONCLUSION: This study suggests that several frequent CNAs in numerous candidate regions are involved in the pathogenesis and metastatic progression of PanNET.
AIM: To investigate the prognostic role of genomic stability and copy number alterations (CNAs) pancreatic neuroendocrine tumors (PanNETs). METHODS: A high-resolution array-based comparative genomic hybridization approach was utilized in order to investigate and quantify chromosomal aberrations in a panel of 37 primary PanNET and 11 metastatic samples. DNA samples were extracted from formalin-fixed and paraffin-embedded tumor specimen. Genomic findings were correlated with histopathological and immunohistochemical data. Moreover, the dataset was subjected to employing an unsupervised hierarchical clustering analysis approach utilizing Euclidean distance and average linkage and associations between genomically defined tumor groups and recurrent CNAs or clinicopathological features of the study group were assessed. RESULTS: Numerous chromosomal aberrations were recurrently detected in both, primary tumor samples and metastases. Copy number gains were most frequently observed at 06p22.2-p22.1 (27.1%), 17p13.1 (20.8%), 07p21.3-p21.2 (18.8%), 09q34.11 (18.8%). Genomic losses were significantly less frequent and the only recurrent aberration affected 08q24.3 (6.3%). Moreover, we detected a high degree of genomic heterogeneity between primary tumors and metastatic lesions. Unsupervised hierarchical clustering of loci affected by CNAs in more than 3 primary tumor samples revealed two genetically distinct tumor groups as well as two chromosomal clusters of genomic imbalances indicating a small subset of tumors with common molecular features (13.5%). Aberrations affecting 6p22.2-22.1, 8q24.3, 9q34.11 and 17p13.1 (P = 0.011; 0.003; 0.003; 0.001), were significantly associated with a poorer survival prognosis. CONCLUSION: This study suggests that several frequent CNAs in numerous candidate regions are involved in the pathogenesis and metastatic progression of PanNET.
Authors: M Gallucci; F Guadagni; R Marzano; C Leonardo; R Merola; S Sentinelli; E M Ruggeri; R Cantiani; I Sperduti; F de la Iglesia Lopez; A M Cianciulli Journal: J Clin Pathol Date: 2005-04 Impact factor: 3.411
Authors: H Aragane; C Sakakura; M Nakanishi; R Yasuoka; Y Fujita; H Taniguchi; A Hagiwara; T Yamaguchi; T Abe; J Inazawa; H Yamagishi Journal: Int J Cancer Date: 2001-12-01 Impact factor: 7.396
Authors: H Schmidt; H Taubert; P Würl; M Kappler; H Lange; F Bartel; M Bache; H-J Holzhausen; R Hinze Journal: Genes Chromosomes Cancer Date: 2002-05 Impact factor: 5.006
Authors: J Zhao; R R de Krijger; D Meier; E J Speel; P Saremaslani; S Muletta-Feurer; C Matter; J Roth; P U Heitz; P Komminoth Journal: Am J Pathol Date: 2000-11 Impact factor: 4.307
Authors: Maria A Kouvaraki; Jaffer A Ajani; Paulo Hoff; Robert Wolff; Douglas B Evans; Richard Lozano; James C Yao Journal: J Clin Oncol Date: 2004-12-01 Impact factor: 44.544
Authors: David R Martin; Elisa LaBauve; Joseph M Pomo; Vi K Chiu; Joshua A Hanson; Rama R Gullapalli Journal: Pancreas Date: 2018-04 Impact factor: 3.327
Authors: Tobias Hofving; Yvonne Arvidsson; Bilal Almobarak; Linda Inge; Roswitha Pfragner; Marta Persson; Göran Stenman; Erik Kristiansson; Viktor Johanson; Ola Nilsson Journal: Endocr Relat Cancer Date: 2018-03 Impact factor: 5.678
Authors: Chi-Chih Kang; Toby M Ward; Jessica Bockhorn; Courtney Schiffman; Haiyan Huang; Mark D Pegram; Amy E Herr Journal: NPJ Precis Oncol Date: 2018-03-22
Authors: Teresa Starzyńska; Jakub Karczmarski; Agnieszka Paziewska; Maria Kulecka; Katarzyna Kuśnierz; Natalia Żeber-Lubecka; Filip Ambrożkiewicz; Michał Mikula; Beata Kos-Kudła; Jerzy Ostrowski Journal: Int J Mol Sci Date: 2020-06-23 Impact factor: 5.923
Authors: Alberto Puccini; Kelsey Poorman; Mohamed E Salem; Davide Soldato; Andreas Seeber; Richard M Goldberg; Anthony F Shields; Joanne Xiu; Francesca Battaglin; Martin D Berger; Ryuma Tokunaga; Madiha Naseem; Afsaneh Barzi; Syma Iqbal; Wu Zhang; Shivani Soni; Jimmy J Hwang; Philip A Philip; Stefania Sciallero; W Michael Korn; John L Marshall; Heinz-Josef Lenz Journal: Clin Cancer Res Date: 2020-09-03 Impact factor: 12.531
Authors: Timon Vandamme; Matthias Beyens; Ken Op de Beeck; Fadime Dogan; Peter M van Koetsveld; Patrick Pauwels; Geert Mortier; Christel Vangestel; Wouter de Herder; Guy Van Camp; Marc Peeters; Leo J Hofland Journal: Br J Cancer Date: 2016-03-15 Impact factor: 7.640